Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc is experiencing a notable increase in projected enterprise value, rising from $2.30 billion to $3.21 billion, which is driven by the anticipated revenue generation from its lead product, deramiocel, in the treatment of Duchenne muscular dystrophy (DMD). The company's innovative therapies show promising clinical outcomes, including a significant 3.3% improvement in left ventricular ejection fraction (LVEF) among patients with cardiomyopathy, suggesting strong market potential and addressing critical unmet medical needs. Additionally, the ongoing development of its proprietary StealthXTM platform enhances its therapeutic offerings in the biotech space, further contributing to a positive outlook for the company’s future financial performance.

Bears say

Capricor Therapeutics Inc faces significant financial challenges that could hinder its growth prospects, including a slower-than-expected market ramp and the potential need for additional equity or debt financing at unfavorable terms, which may lead to dilution. The market potential for the company’s primary product, Deramiocel, may not meet initial projections, raising concerns regarding revenue generation and overall valuation. Furthermore, key risks such as the possibility of failed clinical trials and the inability to secure sufficient funding to advance its therapeutic developments further exacerbate the company’s bleak financial outlook.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.